跳至主要內容
TradingPilot
績效
佈景主題
登入

新聞與行事曆

新聞: 截至 2026-10-13
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分，不是對市場的預測。

已排定事件列上的影響是公司顯著度層級（高/中由圖譜中心度與規模判定；低僅用於人工整理的次要事件），不是對波動幅度的預測。

標記為已確認的財報日期，是 Yahoo Finance 認定由公司確認的；預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業，因此在任何檢視下都會保留。沒有數值的發布表示尚未公布，頁面會直說，而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件；已過去的事件會歸檔，並在可得時補上結果——這些結果都經人工整理並附引用，絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數，或指數基金必須買進的股數，以佔流通股的比例表示——依招股說明書或指數編製方法讀出，兩個數字都在該列註明出處。它陳述的是機制，不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估，直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-13

10月13日週二 · 今天

10月14日週三

過往

已發布 · 最新在前

8月28日週五

融資

11:00
Yahoo Finance

Moderna prices upsized $2.6 billion convertible senior notes offering

Moderna announced the pricing of an upsized offering of $2.6 billion of convertible senior notes. The deal was upsized from the $2.0 billion private placement Moderna proposed the previous day (2026-08-27).

文章預覽

This is a paid press release. Contact the press release distributor directly with any inquiries. Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes · ACCESS Newswire · Moderna, Inc. Moderna, Inc. Fri, August 28, 2026 at 9:00 PM GMT+10 10 min read MRNA Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna has also purchased a hedge overlay intended to offset dil…

Moderna 開啟原文 ↗

合作

10:17
GlobeNewswire

Teva announces proposed acquisition of a novel neuroscience product

Teva announced a proposed acquisition of a novel neuroscience product under its Pivot to Growth strategy. A same-day release from BioXcel Therapeutics announcing an asset sale agreement with Teva Pharmaceuticals identifies the counterparty. Deal terms are not stated in the headline and are not reproduced here.

大盤 開啟原文 ↗

產品

07:00
GlobeNewswire

Roche's Vabysmo shows sustained two-year results in difficult-to-treat nAMD

Roche reported that Vabysmo demonstrated sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration. This is follow-up data on an already-approved product, so it is graded as incremental.

大盤 開啟原文 ↗

合作

06:41
Business Wire

Kioxia and SanDisk to invest more than $31 billion in Japan NAND production

A joint Business Wire release (Chinese-language edition) states that Kioxia and SanDisk will invest more than $31 billion in Japan to consolidate their leadership in the memory/storage industry. No further breakdown of the spend, sites or timing is given in the release headline text carried in the feed.

Kioxia HoldingsSanDisk 開啟原文 ↗

8月27日週四

監管

20:30
GlobeNewswire

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

Pfizer and BioNTech announced U.S. FDA approval of their COVID-19 vaccine adapted to the XFG variant, the strain update for the 2026-2027 season.

文章預覽

Accessibility: Skip TopNav Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine August 27, 2026 16:30 ET | Source: BioNTech SE BioNTech SE 2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to this season’s vaccine NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplem…

Pfizer 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天